Quality of life in cirrhosis

被引：55
作者：
Loria A. [1 ,2 ]
Escheik C. [2 ]
Gerber N.L. [2 ]
Younossi Z.M. [1 ,2 ,3 ]
机构：
[1] Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA
[2] Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA
[3] Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, Falls Church, VA 22042
来源：
Current Gastroenterology Reports | 2013年 / 15卷 / 1期
关键词：
Cirrhosis; HCV; HRQL; Liver; Quality of life;
D O I：
10.1007/s11894-012-0301-5
中图分类号：
学科分类号：
摘要：
Quality of life is a construct that reflects the positive and negative aspects of one's life, and is expanded upon by health-related quality of life (HRQL), which specifically address the impact of health on patients' well-being. Cirrhosis is the culmination of various pathways that leads into development of advanced hepatic fibrosis with its complications. This paper addresses the impact of cirrhosis on individuals HRQL. In addition, we will define what disease specific and general HRQL instruments aim to measure. We discuss the liver disease specific scales [Chronic Liver Disease Questionnaire (CLDQ), Liver Disease Quality of Life 1.0 (LDQOL)] and the most commonly used generic health profile [Short Form 36 Profile (SF-36)]. Furthermore, we examine recent literature which describes how to measure and what is known about quality of life of patients with cirrhosis. This information gives insight to health care providers concerning the impact of disease on patients if treatments are not only to improve health but also function and unexpected treatment outcomes. © 2012 Springer Science+Business Media New York.
引用
收藏
相关论文
共 64 条
[1]  
Davis G.L., Later M.J., El-Serag H., Poynard T., Jennings L.W., Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression, Gastroenterology, 138, pp. 513-521, (2010)
[2]  
Adams L.A., Lymp J.F., St. Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., Angulo P., The natural history of nonalcoholic fatty liver disease: A population-based cohort study, Gastroenterology, 129, 1, pp. 113-121, (2005)
[3]  
Davis G.L., Albright J.E., Cook S.F., Rosenberg D.M., Projecting future complications of chronic hepatitis C in the United States, Liver Transplantation, 9, 4, pp. 331-338, (2003)
[4]  
McGarry L.J., Pawar V.S., Parekh H.H., Et al., Economic model of a birth cohort screening program for hepatitis C virus, Hepatology, 55, pp. 1344-1355, (2012)
[5]  
Rein D.B., Smith B.D., Wittenborn J.S., Lesesne S.B., Wagner L.D., Roblin D.W., Patel N., Ward J.W., Weinbaum C.M., The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings, Ann Intern Med., 156, 4, pp. 263-270, (2012)
[6]  
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965, MMWR Recomm Rep., 61, RR-4, pp. 1-32, (2012)
[7]  
Flegal K.M., Carroll M.D., Kit B.K., Ogden C.L., Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010, JAMA, 307, 5, pp. 491-497, (2012)
[8]  
Younossi Z.M., Stepanova M., Afendy M., Fang Y., Younossi Y., Mir H., Srishord M., Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008, Clin Gastroenterol Hepatol., 9, 6, pp. 524-530, (2011)
[9]  
Rakoski M.O., McCammon R.J., Piette J.D., Iwashyna T.J., Marrero J.A., Lok A.S., Langa K.M., Volk M.L., Burden of cirrhosis on older Americans and their families: Analysis of the health and retirement study, Hepatology, 55, 1, pp. 184-191, (2012)
[10]  
Anthony P.P., Ishak K.G., Nayak N.C., The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization, Journal of Clinical Pathology, 31, 5, pp. 395-414, (1978)
1234567